Genetic myostatin decrease in the golden retriever muscular dystrophy model does not significantly affect the ubiquitin proteasome system despite enhancing the severity of disease

American Journal of Translational Research

Volumn 6, Issue 1, 2014, Pages 43-53

  Cotton, Steven W ^a,c   Kornegay, Joe N ^b   Bogan, Daniel J ^c   Wadosky, Kristine M ^c   Patterson, Cam ^c   Willis, Monte S ^c  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b TEXAS A AND M UNIVERSITY   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Calpain; Dystrophin; Muscular dystrophy; Myostatin; Proteasome; Ubiquitin

Indexed keywords

ATROGIN 1; CALPAIN 1; CALPAIN 2; CASPASE; MUSCLE RING FINGER 1 PROTEIN; MYOSTATIN; PROTEASOME; PROTEIN MDM2; TRYPSIN; UBIQUITIN; UBIQUITIN PROTEIN LIGASE;

ANIMAL EXPERIMENT; ANIMAL MUSCULAR DYSTROPHY; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOG; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; GENE MUTATION; GENETIC VARIABILITY; GOLDEN RETRIEVER MUSCULAR DYSTROPHY; MALE; NONHUMAN; REAL TIME POLYMERASE CHAIN REACTION; SEMEN ANALYSIS;

EID: 84889645549     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Do T. Orthopedic management of the muscular dystrophies. Curr Opin Pediatr 2002; 14: 50-53.
2. McPherron AC and Lee SJ. Double muscling in cattle due to mutations in the myostatin gene. Proc Natl Acad Sci U S A 1997; 94: 12457-12461.
3. Grobet L, Martin LJ, Poncelet D, Pirottin D, Brouwers B, Riquet J, Schoeberlein A, Dunner S, Menissier F, Massabanda J, Fries R, Hanset R and Georges M. A deletion in the bovine myostatin gene causes the double-muscled phenotype in cattle. Nat Genet 1997; 17: 71-74.
4. Mosher DS, Quignon P, Bustamante CD, Sutter NB, Mellersh CS, Parker HG and Ostrander EA. A mutation in the myostatin gene increases muscle mass and enhances racing performance in heterozygote dogs. PLoS Genet 2007; 3: e79.
5. Wagner KR, McPherron AC, Winik N and Lee SJ. Loss of myostatin attenuates severity of muscular dystrophy in mdx mice. Ann Neurol 2002; 52: 832-836.
6. Bogdanovich S, Krag TO, Barton ER, Morris LD, Whittemore LA, Ahima RS and Khurana TS. Functional improvement of dystrophic muscle by myostatin blockade. Nature 2002; 420: 418-421.
7. Qiao C, Li J, Zheng H, Bogan J, Li J, Yuan Z, Zhang C, Bogan D, Kornegay J and Xiao X. Hydrodynamic limb vein injection of adeno-associated virus serotype 8 vector carrying canine myostatin propeptide gene into normal dogs enhances muscle growth. Hum Gene Ther 2009; 20: 1-10.
8. Bish LT, Sleeper MM, Forbes SC, Morine KJ, Reynolds C, Singletary GE, Trafny D, Pham J, Bogan J, Kornegay JN, Vandenborne K, Walter GA and Sweeney HL. Long-term systemic myostatin inhibition via liver-targeted gene transfer in golden retriever muscular dystrophy. Hum Gene Ther 2011; 22: 1499-1509.
9. Krivickas LS, Walsh R and Amato AA. Single muscle fiber contractile properties in adults with muscular dystrophy treated with MYO-029. Muscle Nerve 2009; 39: 3-9.
10. Wagner KR, Fleckenstein JL, Amato AA, Barohn RJ, Bushby K, Escolar DM, Flanigan KM, Pestronk A, Tawil R, Wolfe GI, Eagle M, Florence JM, King WM, Pandya S, Straub V, Juneau P, Meyers K, Csimma C, Araujo T, Allen R, Parsons SA, Wozney JM, Lavallie ER and Mendell JR. A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy. Ann Neurol 2008; 63: 561-571.
11. Prattis SM, Horton SB, van Camp SD and Kornegay JN. Immunohistochemical detection of neural cell adhesion molecule and laminin in X-linked dystrophic dogs and mdx mice. J Comp Pathol 1994; 110: 253-266.
12. Shelton GD and Engvall E. Gross muscle hypertrophy in whippet dogs is caused by a mutation in the myostatin gene. Neuromuscul Disord 2007; 17: 721-722.
13. Kornegay JN, Bogan DJ, Bogan JR, Dow JL, Wang J, Fan Z, Warsing LC, Grange RW, Styner MA, Wagner KR. Disproportionate Muscle Hypertrophy Increases Phenotype Severity in Myostatin-Heterozygous GRMD (GRippet) Dogs. EMBO Workshop - Molecular Mechanisms of Muscle Growth and Wasting in Health and Disease. Ascona, Switzerland. 2011 Sep 18.
14. Kornegay JN, Cundiff DD, Bogan DJ, Bogan JR and Okamura CS. The cranial sartorius muscle undergoes true hypertrophy in dogs with golden retriever muscular dystrophy. Neuromuscul Disord 2003; 13: 493-500.
15. Liu JM, Okamura CS, Bogan DJ, Bogan JR, Childers MK and Kornegay JN. Effects of prednisone in canine muscular dystrophy. Muscle Nerve 2004; 30: 767-773.
16. Bodine SC, Latres E, Baumhueter S, Lai VK, Nunez L, Clarke BA, Poueymirou WT, Panaro FJ, Na E, Dharmarajan K, Pan ZQ, Valenzuela DM, DeChiara TM, Stitt TN, Yancopoulos GD and Glass DJ. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 2001; 294: 1704-1708.
17. Park S, Nozaki K, Guyton MK, Smith JA, Ray SK and Banik NL. Calpain inhibition attenuated morphological and molecular changes in skeletal muscle of experimental allergic encephalomyelitis rats. J Neurosci Res 2012; 90: 2134-45.
18. Fareed MU, Evenson AR, Wei W, Menconi M, Poylin V, Petkova V, Pignol B and Hasselgren PO. Treatment of rats with calpain inhibitors prevents sepsis-induced muscle proteolysis independent of atrogin-1/MAFbx and MuRF1 expression. Am J Physiol Regul Integr Comp Physiol 2006; 290: R1589-1597.
19. Kornegay JN, Tuler SM, Miller DM and Levesque DC. Muscular dystrophy in a litter of golden retriever dogs. Muscle Nerve 1988; 11: 1056-1064.
20. Benvenuti F, Lattanzi F, De Gori A and Tarli P. [Activity of some derivatives of palmitoylethanolamide on carragenine-induced edema in the rat paw]. Boll Soc Ital Biol Sper 1968; 44: 809-813.
21. Bradley L, Yaworsky PJ and Walsh FS. Myostatin as a therapeutic target for musculoskeletal disease. Cell Mol Life Sci 2008; 65: 2119-2124.
22. Patel K and Amthor H. The function of Myostatin and strategies of Myostatin blockade-new hope for therapies aimed at promoting growth of skeletal muscle. Neuromuscul Disord 2005; 15: 117-126.
23. Li ZF, Shelton GD and Engvall E. Elimination of myostatin does not combat muscular dystrophy in dy mice but increases postnatal lethality. Am J Pathol 2005; 166: 491-497.
24. Mendias CL, Bakhurin KI and Faulkner JA. Tendons of myostatin-deficient mice are small, brittle, and hypocellular. Proc Natl Acad Sci U S A 2008; 105: 388-393.
25. Lokireddy S, Wijesoma IW, Bonala S, Wei M, Sze SK, McFarlane C, Kambadur R and Sharma M. Myostatin is a novel tumoral factor that induces cancer cachexia. Biochem J 2012; 446: 23-36.
26. Lokireddy S, Wijesoma IW, Sze SK, McFarlane C, Kambadur R and Sharma M. Identification of Atrogin-1 targeted proteins during the Myostatin-induced skeletal muscle wasting. Am J Physiol Cell Physiol 2012; 303: C512-29.
27. Lokireddy S, Mouly V, Butler-Browne G, Gluckman PD, Sharma M, Kambadur R and McFarlane C. Myostatin promotes the wasting of human myoblast cultures through promoting ubiquitin-proteasome pathway-mediated loss of sarcomeric proteins. Am J Physiol Cell Physiol 2011; 301: C1316-1324.
28. Saez ME, Ramirez-Lorca R, Moron FJ and Ruiz A. The therapeutic potential of the calpain family: new aspects. Drug Discov Today 2006; 11: 917-923.
29. Gailly P, De Backer F, Van Schoor M and Gillis JM. In situ measurements of calpain activity in isolated muscle fibres from normal and dystrophin-lacking mdx mice. J Physiol 2007; 582: 1261-1275.
30. Wadosky KM, Li L, Rodriguez JE, Min JN, Bogan D, Gonzalez J, Patterson C, Kornegay JN and Willis M. Regulation of the calpain and ubiquitin-proteasome systems in a canine model of muscular dystrophy. Muscle Nerve 2011; 44: 553-562.
31. Seehra J. Inhibition of the myostatin pathway for treatment of neuromuscular diseases. MDA National Scientific Conference: Neuromuscular Therapeutic Strategies: Overcoming the Barriers from Microscope to Marketplace. Las Vegas, NV. 2011 Mar 15.
32. Chen YW, Nagaraju K, Bakay M, McIntyre O, Rawat R, Shi R and Hoffman EP. Early onset of inflammation and later involvement of TGFbeta in Duchenne muscular dystrophy. Neurology 2005; 65: 826-834.
33. Zhang Y, Chen Y, Chen JW and Zhu DH. [Altered expression of myostatin gene in the progressive muscular dystrophy patients]. Yi Chuan Xue Bao 2005; 32: 779-783.
34. Tseng BS, Zhao P, Pattison JS, Gordon SE, Granchelli JA, Madsen RW, Folk LC, Hoffman EP and Booth FW. Regenerated mdx mouse skeletal muscle shows differential mRNA expression. J Appl Physiol 2002; 93: 537-545.
35. Chen YW, Zhao P, Borup R and Hoffman EP. Expression profiling in the muscular dystrophies: identification of novel aspects of molecular pathophysiology. J Cell Biol 2000; 151: 1321-1336.
36. Pescatori M, Broccolini A, Minetti C, Bertini E, Bruno C, D'Amico A, Bernardini C, Mirabella M, Silvestri G, Giglio V, Modoni A, Pedemonte M, Tasca G, Galluzzi G, Mercuri E, Tonali PA and Ricci E. Gene expression profiling in the early phases of DMD: a constant molecular signature characterizes DMD muscle from early postnatal life throughout disease progression. FASEB J 2000; 21: 1210-1226.
37. Chamberlain JS, Pearlman JA, Muzny DM, Gibbs RA, Ranier JE, Caskey CT and Reeves AA. Expression of the murine Duchenne muscular dystrophy gene in muscle and brain. Science 1988; 239: 1416-1418.
38. Sharp NJ, Kornegay JN, Van Camp SD, Herbstreith MH, Secore SL, Kettle S, Hung WY, Constantinou CD, Dykstra MJ, Roses AD and Bartlett RJ. An error in dystrophin mRNA processing in golden retriever muscular dystrophy, an animal homologue of Duchenne muscular dystrophy. Genomics 1991; 13: 115-121.
39. Spitali P, van den Bergen JC, Verhaart IE, Wokke B, Janson AA, van den Eijnde R, den Dunnen JT, Laros JF, Verschuuren JJ, 't Hoen PA and Aartsma-Rus A. DMD transcript imbalance determines dystrophin levels. FASEB J 2013 Aug 23; [Epub ahead of print].